Sepracor’s Brovana COPD Therapy Approved; Launch Planned For 2007
Executive Summary
Sepracor's newly approved long-acting beta2-agonist for chronic obstructive pulmonary disease appears to have a slower onset of effect than Novartis/Schering-Plough's Foradil
You may also be interested in...
No Breathing Room For Advair: GSK Combo Part Of Asthma Drug Restrictions
GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products
Novartis Foradil Heart Monitoring Phase IV Required With COPD Approval
Novartis will conduct holter heart monitoring in Foradil Aerolizer patients as a Phase IV commitment following the approval of formoterol for chronic obstructive pulmonary disease Sept. 25.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.